20th Anniversary
Membership
Current Members
Initiatives
Clinical Research Roundtables
COVID-19
CRO Forum
Decentralized Trials
Diversity and Inclusion in Clinical Trials
Risk-Based Quality Management
Advocacy
US Legislation & Regulation
European Legislation & Regulation
Global Data Protection & Privacy
CFO Roundtable
About
ACRO Membership
Our Mission
Leadership
News
Subscribe
Facts & Figures on Clinical Research
Clinical Trial Resources for Patients
Contact Us
RBQM Summary Report
Food and Drug Administration Guidance: COVID-19: Developing Drugs and Biological Products for Treatment or Prevention
June 2, 2020
By
Natalia Gonzalez
Previous Article
Health Canada Guidance: Applications for drug clinical trials under the Interim Order
Next Article
Signant Health White Paper: Strategies for Continued IRT Success During COVID-19